Prescient Therapeutics Ltd (PTX) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Prescient Therapeutics Ltd stock A$0.03, price A$0.05, that is 52.8% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range A$0.0370 – A$0.3000 · the A$0.0540 price screens above the A$0.0255 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Prescient Therapeutics in your weekly email
Every Wednesday you see whether Prescient Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia.
Show moreShow less
Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014.
Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Stock analysis
Prescient Therapeutics Ltd (PTX) currently trades at A$0.0540, while our model-based Fair Value estimate is A$0.0255, 53% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Prescient Therapeutics Ltd reported revenue of A$4.4M in FY2025 versus A$1.2M in FY2021, a compound +38.5%/yr. Reported net income was −A$7.0M in FY2026.
Key figures
Market cap A$56.8M (≈ $39.0M) Micro · P/S ratio 17.2 · EPS (TTM) A$−0.0100 · Return on equity −54.7% · Return on assets (EBIT) −45.5% (5-year average) · Operating margin −138% · Revenue (TTM) A$3.5M · Revenue growth (YoY) −26.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −53%, PTX screens richer than that median.
Fair Value models
BearA$0.0255Fair Value A$0.0255BullA$0.0255
Price A$0.0540 · Downside -52.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)A$0.0100A$0.0100A$0.010055
All 1 models by family
Asset-Based
NCAV (Graham)A$0.0100A$0.0100A$0.010055
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+17.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.5%
Start year 2020 (pandemic). Over 10 years: +59.9% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
’05
’07
’08
’15
’17
’18
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−436.7% (2020) → −173.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Prescient Therapeutics Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Above median
Fair Value upside−52.8% · Below median
Profitability
Return on assets−43.0% · Bottom 25%
Net margin (12 months)−168.1% · Bottom 25%
Operating margin (12 months)−137.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−26.2% · Bottom 25%
Balance sheet
Debt / equity0.06× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B4.00× · Priciest 25%
P/S (12 months)16.45× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)97· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Prescient Therapeutics Ltd (PTX) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of A$0.0255 versus a price of A$0.0540, about 53% lower (overvalued).
What is the fair value of PTX?
Our model-based fair value for Prescient Therapeutics Ltd is A$0.0255 (as of Nov 3, 2026), built from audited fundamentals. The current price: A$0.0540.
What is the quality score of PTX?
Prescient Therapeutics Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prescient Therapeutics Ltd (PTX)?
Our model-based price target is the fair value of A$0.0255 (as of Nov 3, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Prescient Therapeutics Ltd stock forecast for 2026?
Our models put fair value at A$0.0255, about 53% lower versus a price of A$0.0540 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Prescient Therapeutics Ltd (PTX)?
Prescient Therapeutics Ltd reported trailing-twelve-month revenue of about A$3.5M (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Prescient Therapeutics Ltd (PTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prescient Therapeutics Ltd it is A$0.0255 per share (as of Nov 3, 2026), against a price of A$0.0540. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Prescient Therapeutics Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, PTX trades above its calculated fair value: price A$0.0540, fair value A$0.0255, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PTX?
No. The price is what the market pays today (A$0.0540); the fair value is what the company's own numbers justify (A$0.0255). For Prescient Therapeutics Ltd the two are A$0.0285 per share apart. That gap is exactly why we show both numbers side by side.
How much is Prescient Therapeutics Ltd worth?
The market values Prescient Therapeutics Ltd at about A$56.8M (market capitalisation, as of Nov 3, 2026). Per share that is A$0.0540; our models calculate a fair value of A$0.0255 per share.
How solid is the balance sheet of Prescient Therapeutics Ltd (PTX)?
Balance-sheet figures for Prescient Therapeutics Ltd (as of Nov 3, 2026): return on equity −54.7%, debt of 0.06 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is PTX from its 52-week high?
Prescient Therapeutics Ltd trades at A$0.0540, about 49% below its 52-week high of A$0.1050 and 20% above the low of A$0.0450 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0255 is for.
Which stocks are comparable to Prescient Therapeutics Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prescient Therapeutics Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price A$0.0540, calculated fair value A$0.0255 (−53%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PTX calculated?
We run Prescient Therapeutics Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of A$0.0255 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Prescient Therapeutics Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prescient Therapeutics Ltd (PTX)?
The closing price on Nov 6, 2026 was A$0.0540. Our model-based fair value is A$0.0255, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prescient Therapeutics Ltd right now?
The price sits above even our optimistic bull case (A$0.0255). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Prescient Therapeutics Ltd
How large is the market capitalisation of Prescient Therapeutics Ltd (PTX)?
The market capitalisation of Prescient Therapeutics Ltd is A$56.8M (≈ $39.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prescient Therapeutics Ltd (PTX)?
The price-to-sales ratio of Prescient Therapeutics Ltd is 17.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Prescient Therapeutics Ltd (PTX)?
Earnings per share at Prescient Therapeutics Ltd are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Prescient Therapeutics Ltd (PTX)?
The return on equity (ROE) of Prescient Therapeutics Ltd is −54.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prescient Therapeutics Ltd (PTX)?
On an EBIT basis the return on assets of Prescient Therapeutics Ltd is −45.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prescient Therapeutics Ltd (PTX)?
The operating margin of Prescient Therapeutics Ltd is −138% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prescient Therapeutics Ltd (PTX)?
Revenue at Prescient Therapeutics Ltd is growing −26.2% versus a year earlier (3y avg +32.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Prescient Therapeutics Ltd (PTX) generate?
The free cash flow of Prescient Therapeutics Ltd is −A$7.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Prescient Therapeutics Ltd (PTX) hold?
Prescient Therapeutics Ltd holds more cash than debt, A$8.8M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Prescient Therapeutics Ltd in the live analysis
One click puts Prescient Therapeutics Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026
